Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + GEMOX/GC + Lenvatinib vs Capecitabine as Adjuvant Therapy for Biliary Tract Cancer
NCT07679399Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, lenvatinib in biliary tract cancer (BTC), sponsored by Peking Union Medical College Hospital. Started Jun 2025; status: recruiting.
02
Drugs
durvalumablenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07679399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679399.